Zura Bio (NASDAQ:ZURA) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Zura Bio (NASDAQ:ZURA - Free Report) in a report issued on Friday, Benzinga reports.

ZURA has been the topic of a number of other research reports. HC Wainwright initiated coverage on Zura Bio in a report on Thursday, September 5th. They issued a "neutral" rating and a $5.00 target price on the stock. Piper Sandler restated an "overweight" rating and set a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th.

Zura Bio Stock Performance

ZURA traded up $0.03 during trading on Friday, hitting $4.92. 371,328 shares of the company's stock were exchanged, compared to its average volume of 325,853. The business's 50 day moving average is $3.92 and its two-hundred day moving average is $3.95. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). On average, analysts expect that Zura Bio will post -0.47 EPS for the current fiscal year.

Insider Transactions at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the sale, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 15.80% of the company's stock.

Hedge Funds Weigh In On Zura Bio

Several institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in Zura Bio in the third quarter valued at about $62,000. Point72 Asset Management L.P. bought a new stake in shares of Zura Bio in the 2nd quarter worth approximately $8,446,000. Forefront Analytics LLC lifted its stake in Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock valued at $145,000 after purchasing an additional 7,531 shares during the last quarter. AQR Capital Management LLC bought a new position in Zura Bio during the second quarter valued at $43,000. Finally, Armistice Capital LLC grew its holdings in Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after purchasing an additional 876,000 shares during the period. Institutional investors own 61.14% of the company's stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.